PF 07868489
Alternative Names: PF-07868489Latest Information Update: 13 Feb 2024
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Bone morphogenetic protein receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pulmonary arterial hypertension
Most Recent Events
- 13 Feb 2024 PF 07868489 receives Orphan Drug status for Pulmonary arterial hypertension in USA (Pfizer pipeline, February 2024)
- 18 Nov 2023 Preclinical trials in Pulmonary arterial hypertension in USA before November 2023
- 17 Nov 2023 Phase-I clinical trials in Pulmonary arterial hypertension in USA (SC) (NCT06137742)